Latisse is the trade name for a solution of bimatoprost that is being used for the treatment of hypotrichosis of the eyelashes in America. Hypotrichosis is when an individual feels that they do not have enough eyelashes or if they would like to enhance their existing eyelashes. By applying Latisse to the skin at the base of the lash, it causes it each eyelash to grow longer, thicker and darker. Mylash does not currently offer Latisse as there is no current licence to offer bimatoprost that has been branded this way.
Latisse comes with disposable applicators and is in a small eye drop container.
Latisse was first approved by the United States Federal Drugs Association (FDA) in 2008, although it was originally used as a treatment for glaucoma for many years before then.
For FDA approval Latisse had to be intensively studied to determine the safety profile for this cosmetic application. It was found to be safe and effective at growing eyelashes. The average result was a 25% increase in length, 106% increase in thickness and 18% darker lashes.
A lot of press coverage has been generated on the potential for Latisse to cause iris discolouration. During trials, no incident of discolouration was demonstrated and, at the time of writing, Dr Tom Walker has found no evidence of this occurring in a cosmetic application. In 2010 alone, 1.5 million kits of Latisse were sold with no documented proof of iris changes. This does not mean that it cannot happen and if it were to happen, it is thought that the effect would be permanent.
Latisse is a registered trademark of Allergan Inc.